Figure 2.

Flow diagram outlying a provisional ‘roadmap’ for conducting a study to determine whether a given biomarker is a suitable surrogate for a clinical measure of disease progression.

McGhee et al. BMC Neurology 2013 13:35   doi:10.1186/1471-2377-13-35
Download authors' original image